Matricelf Ltd. · TASE:MTLF
Matricelf — Investor Presentation (February 2023)
20 slides from Matricelf's investor presentation, February 2023
Slide 1: Autologous 3D Engineered Tissues
Autologous 3D Engineered Tissues (TASE:MTLF) Corporate Presentation
Slide 2: Statement Looking Forward and Disclosure
Statement Looking Forward and Disclosure This presentation was prepared by Matricelf Ltd. (“The Company”), as a general presentation about The Company, as such, the information it includes is only an extract, and does not cover all of the information about The Company and its operations. Therefore,
Slide 3: Company Vision: Curing the Incurable
Company Vision Curing the Incurable Innovative regenerative medicine company, helping millions of patients worldwide
Slide 4: Matricelf Introduction
Matricelf Introduction • Regenerative Medicine company • Developing 3D engineered tissue implants • Spin-out company from Tel Aviv University (Dvir Lab, Nanotechnology Center: more than 10 years of academic research & USD ~12M in research grants) • Established April 2019
Slide 5: Proprietary Technologies
Proprietary Technologies Autologous 3D implants: • Integration of autologous matrix and cells • Matrix - Thermo-responsive autologous hydrogel • Cells - In-gel differentiation of autologous induced Pluripotent Stem Cells (iPSC) • Engineered tissues for numerous medical indications 3D bioprinting of
Slide 6: Spinal Cord Injury (SCI)
Spinal Cord Injury (SCI) matrice
Slide 7: SCI Program Highlights
SCI Program Highlights Unmet need • No available treatment for SCI - irreversible loss of motor/sensory/autonomic functions • Most potential therapies are synthetic/allogeneic which may lead to immune rejection Our solution • 100% autologous tissue engineered product • Personalized treatment, reduce
Slide 8: Matricelf Platform Generates Autologous Functioning 3D Neural Implants for SCI
Matricelf Platform Genetares Autologous Functioning 3D Neural Implants for SCI induced Pluripotent Stem Cells Extra Cellular Matrix
Slide 9: Functional Neural Implant
Functional Neural Implant ✓ Incorporation of iPSCs within extracellular matrix followed by controlled differentiation ✓ New synapses and neurons generate a neural network ✓ Matured 3D tissue formed 1 mm 500 μm Lior Wertheim, Adv. Sci. 2022
Slide 10: Neural Implants Restore Function
Neural Implants Restore Function • Follow up: 2 months post spinal hemisection in mice • “Cat walk” – four limbs motor function and gait analysis • Control group – hemiparesis (circled in red) • Mice treated with neural implants regained their walking abilities Control Lior Wertheim, Adv. Sci. 2022
Slide 11: Competitive Therapeutic Landscape
Competitive Therapeutic Landscape Analysis of alternative technologies AMEX: LCTX NSDQ:NVIV Autologous cells Pluripotent cells Autologous scaffold 3D structure Matricelf develops a one-of-a-kind technology that produces functioning, completely autologous, 3D neural implants
Slide 12: Company Roadmap
Company Roadmap FIH Regulatory GMP Engineering approval for runs phase I/IIa clinical trial Safety GLP animal study Pilot efficacy Efficacy animal study animal study Neural implants In vitro development POC New IPO lab Pre-IND meeting Decade of Tech transfer research at TAU → Matricelf Confidential
Slide 13: Key Achievements: 2022
Key Achievements: 2022 ✓ Development of human hydrogel ✓ Development of human iPSC lines ✓ Development of human neural implant ✓ Usability study in pigs in collaboration with Johns Hopkins Medical school ✓ Three granted patents, two new patents application submitted ✓ Completed technology transfer o
Slide 14: Projected Milestones: 2023
Projected Milestones: 2023 • Completion of pilot efficacy study • Completion of pilot safety study • Completion of formulation development • Initiation of POC efficacy study • Pipeline broadening – New indication
Slide 15: The Team
The Team ASAF TOKER, MD TAL DVIR, PhD TAMAR HAREL ADAR, PhD CEO Founder, CSO VP R&D TAL BEN NERIAH, MSc SIGAL RUSSO, CPA ALON SINAI VP of Operations CFO Founder, Deputy CEO
Slide 16: Board of Directors
Board of Directors DORON BIRGER RUTH ARNON, PhD TAL DVIR, PhD NEOMI ENOCH, CPA Chairman Board member Board member Board member STANLEY HIRSCH, PhD SUZANA NAHUM-ZILBERBERG, CPA ALON SINAI Board member Board member Board member
Slide 17: Scientific Advisory Board
Scientific Advisory Board MARK TUSZYNSKI, MD PhD KAPIL BHARTI, PhD Director of The Center for Senior researcher at the Neural Repair, University of National Institutes of Health California, San Diego ("NIH"), an expert in the use of ECKHARD VON KEUTZ, PhD induced pluripotent stem cells Chairman of t
Slide 18: Summary
Summary Unique advantages • Autologous treatment • 3D engineered tissue implants (cells and matrix) • Cell/iPSC differentiation within a 3D structure • Support medium enabling 3D bioprinting Main programs • Spinal Cord Injury (SCI) • 3D bioprinting IP status • 3 granted patents, 7 pending applicatio
Slide 19: Watch our corporate video
Watch our corporate video at: https://youtu.be/XUGfveypuAs
Slide 20: Thank you
Thank you www.matricelf.com info@matricelf.com